PeptidePedia The community reference

Subcutaneous injection: difference between revisions

Diff·revision 10 → 11·15:20, 22 Nov 2024

Difference between revision 10 and revision 11 of Subcutaneous injection. 10 lines changed; the page grew by 704 bytes.

Revision 10 — 20:51, 4 Nov 2024
ArchiveBot (talk)
bot: normalise unit spacing
2,986 bytes ±0
Revision 11 — 15:20, 22 Nov 2024
StubSorterBot (talk)
bot: repair redlinked category
3,690 bytes +704
21Volume is limited by the compliance of the tissue. More than about 1.5 mL at one site produces discomfort and a visible bleb, and larger volumes are split. Peptide doses in this field are usually well under that, since a few milligrams of peptide occupy a very small volume at ordinary reconstitution concentrations.{{r|richter2012,usp1503}}21Volume is limited by the compliance of the tissue. More than about 1.5 mL at one site produces discomfort and a visible bleb, and larger volumes are split. Peptide doses in this field are usually well under that, since a few milligrams of peptide occupy a very small volume at ordinary reconstitution concentrations.{{r|richter2012,usp1503}}
2222
+23== Site differences ==
+24| Site | Relative absorption rate | Notes |
+25|---|---|---|
+26| Abdomen | Fastest | Avoiding the immediate periumbilical area is conventional |
+27| Upper arm | Intermediate | Subcutaneous layer may be thin |
+28| Thigh | Slower | Exercise increases local flow |
+29| Buttock | Slowest | Consistent, less affected by activity |
+30
+31Differences of this kind are established for insulin and are commonly extrapolated to other subcutaneous preparations. The extrapolation is reasonable but is an extrapolation: for a peptide whose absorption half-life is long relative to its elimination half-life, site differences are absorbed into the profile and become clinically undetectable.{{r|richter2012}}
+32
23== References ==33== References ==
24{{reflist}}34{{reflist}}